AnaptysBio
ANAB
119 hedge funds and large institutions have $1.02B invested in AnaptysBio in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 23 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 33
10% more call options, than puts
Call options by funds: $20.3M | Put options by funds: $18.6M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.36% less ownership
Funds ownership: 111.73% → 107.36% (-4.4%)
6% less funds holding
Funds holding: 127 → 119 (-8)
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
40% less capital invested
Capital invested by funds: $1.7B → $1.02B (-$687M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.9M |
| 2 |
Morgan Stanley
New York
|
+$9.19M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.67M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$7.07M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$36M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$32.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$13.1M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$10.6M |
| 5 |
Jennison Associates
New York
|
-$9.16M |
ANAB Hedge Fund Activity: Q3 2019 in Review
119 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2019, worth a combined $1.02B — down 40% from $1.7B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ANAB and 16 opened new positions — a net loss of 7 holders — while 33 trimmed existing stakes and 54 added.
The largest buyer was Vanguard Group, adding an estimated $10.9M. The largest seller was Invesco, cutting an estimated $36M.
- 119 institutional investors held AnaptysBio (ANAB) as of Q3 2019, down from 127 in Q2 2019.
- Funds reported $1.02B of AnaptysBio stock for Q3 2019, down 40% quarter-over-quarter.
- 16 funds opened new AnaptysBio positions in Q3 2019 and 23 closed out, a net change of -7 holders.
- The largest AnaptysBio buyer in Q3 2019 was Vanguard Group, an estimated $10.9M added.
- The largest AnaptysBio seller in Q3 2019 was Invesco, an estimated $36M sold.
Based on aggregated 13F filings for Q3 2019.